Chidamide With Immunotherapy for Patients With Locally Advanced or Metastatic Urothelial Carcinoma

StatusCompleted
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion date changed from estimate of Oct 30, 2025 to Aug 18, 2026
    • Trial completed
    • Eligibility criteria expanded, about 24 words
    • Publications: details revised at 4 of 4 entries
  2. Primary completion date changed from estimate of Sep 30, 2022 to Aug 30, 2024v3 Show 6 more changesShow less
    • Start date changed from estimate of Oct 1, 2020 to Jan 1, 2021
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: 43 to 45
    • Study completion date: Sep 30, 2023 to Oct 30, 2025
    • Interventions: Chidamide with tislelizumab (Drug) to Chidamide (Drug)
    • Site details revised
  3. Start date: Sep 24, 2020 to Oct 1, 2020v2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Study of Chidamide Combined With Immunotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Who Had Previously Received Platinum-based Chemotherapy
Trial Details
NCT Number NCT04562311
Lead Sponsor Sun Yat-sen University
Conditions
(from sponsor)		 Bladder Cancer Stage IV
Related terms Urinary Bladder Neoplasms
Enrollment 45 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov